BioCentury
ARTICLE | Financial News

Bellicum sets IPO terms

December 10, 2014 2:59 AM UTC

Bellicum Pharmaceuticals Inc. (Houston, Texas) set terms for its IPO on NASDAQ and now plans to sell 6.25 million shares at $15-$17. At $16, Bellicum would raise $100 million and be valued at $396.5 million. Jefferies; Citigroup; Piper Jaffray; and Trout Capital are underwriters.

The company is conducting Phase I/II testing of BPX-501, a therapy comprising T cells containing the company's CaspaCIDe gene that is designed to eliminate donor T cells associated with toxicity in hematopoietic stem cell transplant (HSCT) patients. Bellicum's BPX-201, which consists of genetically modified, autologous dendritic cells targeting prostate cancer cells, is in a Phase I trial to treat metastatic castration-resistant prostate cancer (CRPC). ...